These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37690312)

  • 1. Augmentation of learning in schizophrenia by d-serine and auditory remediation is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study.
    Govani V; Shastry AM; Iosifescu DV; Govil P; Mayer MR; Sobeih T; Choo TH; Wall MM; Sehatpour P; Kantrowitz JT
    Schizophr Res; 2023 Oct; 260():205-208. PubMed ID: 37690312
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine.
    Sehatpour P; Iosifescu DV; De Baun HM; Shope C; Mayer MR; Gangwisch J; Dias E; Sobeih T; Choo TH; Wall MM; Medalia A; Saperstein AM; Kegeles LS; Girgis RR; Carlson M; Kantrowitz JT
    Biol Psychiatry; 2023 Jul; 94(2):164-173. PubMed ID: 36958998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of learning in schizophrenia by D-serine is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study.
    Govani V; Shastry A; Iosifescu D; Govil P; Mayer M; Sobeih T; Choo T; Wall M; Sehatpour P; Kantrowitz J
    Res Sq; 2023 May; ():. PubMed ID: 37293030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grant Report on d-Serine Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia
    de la Garrigue N; Glasser J; Sehatpour P; Iosifescu DV; Dias E; Carlson M; Shope C; Sobeih T; Choo TH; Wall MM; Kegeles LS; Gangwisch J; Mayer M; Brazis S; De Baun HM; Wolfer S; Bermudez D; Arnold M; Rette D; Meftah AM; Conant M; Lieberman JA; Kantrowitz JT
    J Psychiatr Brain Sci; 2020; 5(4):. PubMed ID: 32856005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
    Kantrowitz JT; Epstein ML; Lee M; Lehrfeld N; Nolan KA; Shope C; Petkova E; Silipo G; Javitt DC
    Schizophr Res; 2018 Jan; 191():70-79. PubMed ID: 28318835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.
    Kantrowitz JT; Swerdlow NR; Dunn W; Vinogradov S
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2018 Jul; 3(7):581-590. PubMed ID: 29656951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
    J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine.
    Kantrowitz JT; Epstein ML; Beggel O; Rohrig S; Lehrfeld JM; Revheim N; Lehrfeld NP; Reep J; Parker E; Silipo G; Ahissar M; Javitt DC
    Brain; 2016 Dec; 139(Pt 12):3281-3295. PubMed ID: 27913408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.
    Lane HY; Lin CH; Huang YJ; Liao CH; Chang YC; Tsai GE
    Int J Neuropsychopharmacol; 2010 May; 13(4):451-60. PubMed ID: 19887019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.
    O'Donnell P; Dong C; Murthy V; Asgharnejad M; Du X; Summerfelt A; Lu H; Xu L; Wendland JR; Dunayevich E; Buhl DL; Litman R; Hetrick WP; Hong LE; Rosen LB
    Neuropsychopharmacology; 2023 Jun; 48(7):1052-1059. PubMed ID: 36928351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
    Light GA; Zhang W; Joshi YB; Bhakta S; Talledo JA; Swerdlow NR
    Neuropsychopharmacology; 2017 Dec; 42(13):2633-2639. PubMed ID: 28425497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine effects on auditory discrimination and training in schizophrenia patients.
    Swerdlow NR; Bhakta SG; Talledo J; Kotz J; Roberts BZ; Clifford RE; Thomas ML; Joshi YB; Molina JL; Light GA
    Neuropsychopharmacology; 2020 Dec; 45(13):2180-2188. PubMed ID: 32961542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-serine added to antipsychotics for the treatment of schizophrenia.
    Tsai G; Yang P; Chung LC; Lange N; Coyle JT
    Biol Psychiatry; 1998 Dec; 44(11):1081-9. PubMed ID: 9836012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients.
    Swerdlow NR; Tarasenko M; Bhakta SG; Talledo J; Alvarez AI; Hughes EL; Rana B; Vinogradov S; Light GA
    Schizophr Bull; 2017 Jul; 43(4):872-880. PubMed ID: 27798224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial.
    Kantrowitz JT; Woods SW; Petkova E; Cornblatt B; Corcoran CM; Chen H; Silipo G; Javitt DC
    Lancet Psychiatry; 2015 May; 2(5):403-412. PubMed ID: 26360284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial.
    Durgam S; Earley W; Li R; Li D; Lu K; Laszlovszky I; Fleischhacker WW; Nasrallah HA
    Schizophr Res; 2016 Oct; 176(2-3):264-271. PubMed ID: 27427558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment.
    Vayısoğlu S; Anıl Yağcıoğlu AE; Yağcıoğlu S; Karahan S; Karcı O; Gürel SC; Yazıcı MK
    Schizophr Res; 2013 Jan; 143(1):207-14. PubMed ID: 23217729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.